Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | NCF1 | P14598 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.43 |
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15810094 | 0.88 | MAPT (0.45) | LOXL2NCF1MAPTTP53SMN1; SMN2 | |
| SCHEMBL14532288 | 0.85 | LOXL2 (0.48) | LOXL2NCF1HTR1AADRA1DADRA1A | |
| SCHEMBL263407 | 0.82 | LOXL2 (0.50) | LOXL2NCF1HTR1AADRA1DADRA1A | |
| SCHEMBL8908132 | 0.82 | LOXL2 (0.50) | LOXL2NCF1HTR1AADRA1DADRA1A | |
| SCHEMBL24700723 | 0.82 | LOXL2 (0.46) | LOXL2NCF1HTR1AADRA1DADRA1A | |
| SCHEMBL7021926 | 0.82 | LOXL2 (0.46) | LOXL2NCF1HTR1AADRA1DADRA1A | |
| SCHEMBL14122720 | 0.81 | NCF1 (0.52) | LOXL2NCF1HTR1AADRA1DADRA1A | |
| SCHEMBL264120 | 0.81 | NCF1 (0.52) | LOXL2NCF1HTR1AADRA1DADRA1A | |
| SCHEMBL13868218 | 0.81 | NCF1 (0.52) | LOXL2NCF1HTR1AADRA1DADRA1A | |
| SCHEMBL14120837 | 0.81 | NCF1 (0.52) | LOXL2NCF1HTR1AADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134004-B2 | Substituted N-bicyclicalkyl bicycliccarboxyamide compounds | PFIZER INC. (US) | 2012-03-13 | — | — | US | disclosed |
| EP-1554239-B1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-01-26 | — | — | EP | disclosed |
| US-20090253740-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS | PFIZER INC | 2009-10-08 | — | — | US | disclosed |
| EP-2044018-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLIC CARBOXYAMIDE COMPOUNDS | Pfizer Japan, Inc. (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-7435815-B2 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-10-14 | — | — | US | disclosed |
| WO-2008007211-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLIC CARBOXYAMIDE COMPOUNDS | PFIZER JAPAN INC. (JP) | 2008-01-17 | — | — | WO | disclosed |
| US-20070244156-A1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-18 | — | — | US | disclosed |
| US-7279578-B2 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-09 | — | — | US | disclosed |
| US-20060014783-A1 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2006-01-19 | — | — | US | disclosed |
| EP-1554239-A2 | SULFONYLAMINO-ACETIC ACID DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004033418-A2 | SULFONYLAMINO-ACETIC DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014783-A1 | Sulfonylamino-acetic acid derivatives | HCRTR2, HCRTR1, GIPR | LOXL2 4004/4885NCF1 4075/4885HTR1A 104/4885 |
| US-20090253740-A1 | SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS | OPRL1, CNR1, TRPV1 | LOXL2 2596/4885NCF1 1434/4885HTR1A 164/4885 |
| US-20070244156-A1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES | HCRTR2, HCRTR1, GIPR | LOXL2 4004/4885NCF1 4075/4885HTR1A 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.